Center-Authored Papers

Filters: Author is Faderl, Stefan  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Vidarabine
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
Vegetables
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Tretinoin
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
Treatment Outcome
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M et al..  2010.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):549-55. Abstract
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Time Factors
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Tandem Repeat Sequences
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM et al..  2013.  A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.. British journal of haematology. 163(1):130-2.
Survival Rate
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M et al..  2010.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):549-55. Abstract
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
Survival Analysis
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Specimen Processing Core Facility
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Shared Resources
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Risk Factors
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Research Trials Office Core Facility - Biostatistics Service
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Remission Induction
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.  2008.  Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.. Leukemia research. 32(10):1505-9. Abstract
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M et al..  2010.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):549-55. Abstract